CYP19A1 and Hepatic steatosis: Results across multiple cohorts suggested robust, consistent and durable pharmacodynamic effects through at least 12 weeks, after single (day 1) or repeat (days 1 and 29) doses of ARO-ANG3 in HPs and repeat (days 1 and 29) doses for hepatic steatosis cohorts.